Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Minno, Giovanni, Navarro, David, Perno, Carlo Federico, Canaro, Mariana, Gürtler, Lutz, Ironside, James W., Eichler, Hermann, Tiede, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486800/
https://www.ncbi.nlm.nih.gov/pubmed/28624906
http://dx.doi.org/10.1007/s00277-017-3028-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486800/
https://www.ncbi.nlm.nih.gov/pubmed/28624906
http://dx.doi.org/10.1007/s00277-017-3028-4

Ejemplares similares